Novartis Hid Manipulated Data While Seeking Approval for $2.1 Million Treatment

The failure to report the issue has not put patients at risk, the F.D.A. said, but the drugmaker could face criminal and civil penalties. KATIE THOMAS https://ift.tt/2M3PJn4 https://ift.tt/2YLU8Ry The New York Times Health Drugs (Pharmaceuticals), Genetics and Heredity, your-feed-healthcare August 6, 2019 at 02:00AM